| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000413 | BKPyv | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS10015861 | HBV | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS10025821 | HBV | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS10020575 | HBV | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS20047074 | HPV | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS20047753 | HPV | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS20043035 | HPV | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
| TVIS44035632 | HTLV-1 | ENSG00000162368.15 | protein_coding | CMPK1 | No | No | 51727 | B2R6S5 P30085 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CMPK1 |
|---|---|
| DrugBank ID | DB03435 |
| Drug Name | Uridine-5'-Diphosphate |
| Target ID | BE0000637 |
| UniProt ID | P30085 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 10592235 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. |
| Groups | Experimental |
| Direct Classification | Pyrimidine ribonucleoside diphosphates |
| SMILES | O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(=O)OP(O)(O)=O)N1C=CC(=O)NC1=O |
| Pathways | Krabbe Disease; Acetaminophen Metabolism Pathway; Fabry Disease; Etoposide Action Pathway; Amino Sugar Metabolism; Codeine Action Pathway; Lamivudine Metabolism Pathway; MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy); Hereditary Coproporphyria (HCP); Sphingolipid Metabolism; Salla Disease/Infantile Sialic Acid Storage Disease; Glycogenosis, Type IV. Amylopectinosis, Anderson Disease; Porphyrin Metabolism; G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease; Tamoxifen Action Pathway; Celecoxib Action Pathway; Gaucher Disease; Congenital Erythropoietic Porphyria (CEP) or Gunther Disease; Valproic Acid Metabolism Pathway; Androgen and Estrogen Metabolism; Pyrimidine Metabolism; Congenital Disorder of Glycosylation CDG-IId; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Glycogenosis, Type VI. Hers Disease; Aromatase Deficiency; Starch and Sucrose Metabolism; Sorafenib Metabolism Pathway; Galactose Metabolism |
| PharmGKB | |
| ChEMBL | CHEMBL130266 |
